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Abstract
Understanding resistance to antifungal agents in Aspergillus fumigatus is of increasing importance for the treatment of
invasive infections in immunocompromised patients. Although a number of molecular resistance mechanisms are described
in detail, the potential accompanying virulence changes and impact on clinical outcome have had little attention. We
developed a new measure of survival, the composite survival index (CSI) to use as a measure of the virulence properties of A.
fumigatus. Using a novel mathematical model we found a strong correlation between the in vitro growth characteristics and
virulence in vivo expressed as CSI. Our model elucidates how three critical parameters (the lag phase (t), decay constant (l),
and growth rate (n)) interact with each other resulting in a CSI that correlated with virulence. Hence, strains with a long lag
phase and high decay constant were less virulent in a murine model of invasive aspergillosis, whereas high virulence for
isolates with a high CSI was associated in vitro with rapid growth and short lag phases. Resistant isolates with cyp51A
mutations, which account for the majority of azole resistant aspergillosis cases, did not show a lower virulence compared to
azole-susceptible isolates. In contrast, the CSI index revealed that a non-cyp51A-mediated resistance mechanism was
associated with a dramatic decrease in CSI. Because of its predictive value, the mathematical model developed may serve to
explore strain characteristics in vitro to predict virulence in vivo and significantly reduce the number of experimental
animals required in such studies. The proposed measure of survival, the CSI can be used more in a general form in survival
studies to explore optimal treatment options.
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Introduction
Aspergillus fumigatus is responsible for the majority of invasive
fungal infections in immunocompromised patients. Timely treat-
ment with antifungal drugs is essential for the management of this
disease and numerous efficacy studies have been carried out both
in animals and humans to support evidence-based treatment
choices [1,2,3]. To date, most investigations into antifungal
efficacy have concentrated upon growth inhibition (MIC) whereas
the role of fungal virulence has been largely ignored. The role of
virulence as a factor in the disease outcome of patients with
aspergillosis has hardly been considered, despite data obtained for
other microorganisms indicating that the factor virulence may
affect treatment [4,5,6].
The recent emergence of acquired resistance of A. fumigatus to
medical triazoles [7,8,9,10,11,12,13,14], has drawn attention to
the question whether the evolution of azole resistance has any
impact on the ability of the fungus to cause infection in man, and
subsequently, on the clinical outcome. A link between azole drug
resistance and the virulence of A. fumigatus was first demonstrated
by Willger and colleagues [15]. Loss of SrbA, a sterol regulatory
element binding protein resulted in growth incapacity of A.
fumigatus and inability to cause fatal infections in two murine
models of invasive pulmonary aspergillosis [16]. Further exami-
nation of the SrbA null mutant revealed that SrbA played a critical
role in resistance to the azoles. Moreover, we recently reported
reduced virulence in clinical A. fumigatus isolates that had become
resistant to azoles during azole therapy [17]. A reduction of
virulence in the above-mentioned studies was observed in non-
cyp51A gene associated resistance mechanisms, while cyp51A-
associated short nucleotide polymorphisms (SNPs) are the most
prevalent resistance mechanism in clinical A. fumigatus isolates.
Numerous SNPs in the cyp51A gene have been reported in clinical
A. fumigatus isolates [18,19,20,21], which confer increased minimal
inhibitory concentrations (MIC) for azoles in vitro and reduced
azole efficacy in vivo [22,23]. Although A. fumigatus isolates with
cyp51A mutations cause invasive aspergillosis in humans, indicating
their ability to cause infection, quantitative estimates of in vivo
virulence of isolates harboring those mutations are lacking [24].
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A standardized animal model to compare the virulence of
different A. fumigatus isolates is absent. It has been shown previously
that variation in virulence between A. fumigatus isolates exists in a
murine infection model but this study did not report susceptibility
data [25] and other models previously used for measuring
virulence reported unsatisfactory results [26].
In the present study, we investigated whether cyp51A-associated
azole resistance mechanisms favored a gain or loss of virulence in
A. fumigatus. To that purpose, we used a simple in vivo non-
neutropenic murine model of disseminated aspergillosis. In
particular, we explored the effects of in vitro growth characteristics
on survival and developed a novel mathematical model. We
propose and describe a new composite survival index (CSI) that
enabled the prediction of survival in the animal model. The CSI
was subsequently used to determine the impact of resistance
mechanisms on the virulence of A. fumigatus.
Materials and Methods
Isolates
Thirty clinical A. fumigatus isolates from different patients and
hospitals were used in this study (Table S1). Microsatellite
genotyping showed no genetic relationship among all isolates
(Table S1). Ten isolates were defined as wild type based on the
in vitro susceptibility profile and absence of mutations in the cyp51A
gene (Table S1). Twenty isolates were defined as non-wild type
based on the in vitro susceptibility profile and the presence of
mutations in the cyp51A shown to be associated with azole
resistance.
From the collection of the aforementioned 30 isolates, we used
in total 15 clinical isolates for the in vivo studies; three WTs (V28–
29, V52–76, AZN 8196), three isolates were used that harbored
the TR34/L98H resistance mechanism, which are believed to be
selected through exposure to azole fungicides in the environment
[9]. This mechanism was found to be the dominant resistance
mechanism in clinical isolates in the Netherlands, other European
countries and in Asia [27,28,29] and has also been found in azole-
resistant isolates recovered from the environment [8,30].
Five isolates harbored SNPs in cyp51A, which were selected
during azole therapy, including substitutions at codon M220 (28–
77 with M220I, v13-09 with M220V, v59-07 with M220K), codon
G54 (G54W, isolate v59–73), and codon 138 (G138C, isolate v59–
72). In addition, four isogenic A. fumigatus isolates used were
cultured serially from a single patient (isolates S1, S2, R1, and R2)
[17]. The patient had chronic granulomatous disease (CGD) and
was treated with multiple regimens of antifungal azoles for a
chronic pulmonary Aspergillus infection. On antifungal therapy, the
azole susceptibility changed from a wild-type phenotype (S1 and
S2) to a resistant phenotype (R1 and R2). Although the expression
of the cyp51A gene in the isolates R1 and R2 was elevated
compared with the S1 and S2 isolates, no SNPs were found in
cyp51A [17]. All isolates were stored in 10% glycerol broth at
280uC and were revived by subculturing on Sabouraud dextrose
agar (SAD) supplemented with 0.02% chloramphenicol for 5 to 7
days at 35uC.
Molecular Analysis
The morphological identification of the A. fumigatus isolates was
confirmed by sequencing of the b-tubulin and calmodulin genes,
as described previously [8]. Genetic relationships of all isolates
were determined by microsatellite genotyping (Table S1) [31].
This previously described assay relied on the variability of STRs in
the A. fumigatus genome. Three trinucleotide and three tetranucle-
otide repeats of six different loci were amplified by using
fluorescently labeled primers. The amplified DNA fragments were
determined by the addition of the GeneScan LIZ [500] marker
and were analyzed with the Applied Biosystems 3730 DNA
software system. The assignment of repeat numbers in each
marker was determined from GeneScan data by using Peak
Scanner version 1.0 software (Applied Biosystems). The cyp51A
coding region and its promoter were sequenced as previously
described [18,32].
In vitro Studies
Antifungal susceptibility testing was performed based on the
M38-A2 method of the Clinical Laboratory Standards Institute
(CLSI) by using a microbroth dilution format and MICs of
voriconazole, posaconazole, and itraconazole were determined
as the lowest drug concentration resulting in no visible growth
after incubation for 48 h [33]. In vitro growth curves of the
thirty isolates were determined by using a previously described
microbroth kinetic system [34,35]. OD measurement can be
used to quantify Aspergillus growth and it describes changes in
fungal biomass. Briefly, 96-well microtitration plates were
inoculated with 200 mL of RPMI1640 with 0.165 M MOPS
containing 2.56104 conidia. To prevent evaporation, the
vertical margins of the microtiter plates were sealed with
autoclave sterilization tape. After agitation for 15 s the
suspensions were incubated at 37uC inside a plate reader
(Rosys Anthos ht3; Anthos Labtec Instruments GmbH, Salz-
burg, Austria) for 90 h. The optical density at 405 nm (OD)
was automatically recorded for each well every 15 min. The
changes in OD over time were used to generate growth curves
for each isolate in triplicate (OD-growth). All studies were
conducted twice. The mean value was used for statistical
analyses.
In vivo Studies
To compare the in vivo virulence of each A. fumigatus isolate, a
previously described experimental murine model of disseminated
aspergillosis was used [17,22]. A subset of 15 out of the 30 A.
fumigatus strains was chosen based on the azole resistance
mechanism and the duration of the lag phase, which was recently
implicated as an important marker to predict virulence [17]. A
total of 660 outbred CD-1 female mice (20–25 g, 4–5 weeks old)
were randomized into 60 groups (n = 11 per group). Each of these
groups was infected intravenously by the tail vein with four
different inocula of the aforementioned isolates: concentrations of
16106, 56106, 16107, and 56107 CFU per mouse. Post-infection
viability counts of the injected inocula were determined to ensure
that the correct inoculum had been injected. Mortality was
monitored for 15 days. On day 15 post-infection, all remaining
mice were humanely euthanized by cervical dislocation. To assess
the variability of in vivo studies, A. fumigatus isolates with different
azole resistance mechanisms (the wild type, G54W, TR34/
L98H_v52–35, and the M220I isolate) were tested in triplicate at
a low (16106 CFU per mouse) and a high (56107 CFU per mouse)
inoculum. The differences in percentage of survival and MST
were ,10% and ,1 day among replicates, indicating very high
reproducibility.
The animals were housed under standard conditions with water
and food supplied ad libitum. Animal studies were carried out in
strict accordance with the recommendations of the European
Community (Directive 86/609/EEC, 24 November 1986). The
protocol was approved by Animal Welfare Committee of the
Radboud University (RU-DEC 2007-106). All efforts were made
to minimize suffering. To prevent severe discomfort and substan-
tial distress, throughout the whole study mice were monitored and
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clinically inspected several times day and night. The experiment
was immediately terminated if the humane endpoints were not
fulfilled. Symptoms of discomfort and distress included loss of
weight (15% loss within 72 h or 20% within 48 h); very high or
very low body temperature; desiccation; lethargy; hyperactivity in
terms of spinning around in circles constantly; eyes turning black;
reduced mobility, and therefore, mice are unable to reach food or
drink; or generally reduced food/water intake. All stressed animals
were sacrificed by cervical dislocation. The murine model of
disseminated aspergillosis is well established in our laboratory.
Therefore, the veterinary experts and investigators are able to
recognize the clinical symptoms in the animals at a very early stage
and can ensure early termination before the humane endpoints are
reached without affecting interpretation of the experimental
results.
Modeling of the in vitro Growth in A. fumigatus
In vitro growth curves were analyzed with nonlinear regression
analysis based on a novel mathematical model of fungal growth.
Previous reports suggested Malthusian fitness as a possible
measure model of fungal fitness [36]. This function assumes that
the size of the population is limited by an asymptotic maximum
(plateau). However, because the previous and our present growth
kinetic experiments showed that a plateau phase was not reached,
we set out to define a new model that better described the
observed growth [34,35,37]. This model incorporated a piecewise
function of 1) the lag phase (t), which corresponded to no OD-
growth changes observed until the hyphal length reached 70 mm;
and 2) the growth phase of the fungus, which corresponded to
OD-growth changes post t. The lag phase was described as a
constant function. The growth phase was modeled by the function
composed of two main factors: linear OD growth and exponential
decay. With these factors, the model reasonably captures the
dynamics of the growth phase and the death phase which are
constantly and simultaneously present during the life cycle of a cell
population which is composed of a heterogeneous population of
aging cells. The underlying assumptions of our model are currently
utilized in prediction models for other cell types and organisms
which take into account the variability in the aging process of the
cells. To the best of our knowledge there has been no similar
model for filamentous fungi allowing the modeling of the whole life
cycle.
Thus, the proposed model for simulating the growth of
A. fumigatus in vitro is defined by Equation 1:
Y (t)~
Y0 ; tvt
(Y0zn(t{t)) exp ({l(t{t)) ; t§t
8<
: ð1Þ
where Y(t) represents the fungal biomass assessed based on the
optical density at time t. For the mathematical growth function
parameters, Y0 corresponded to the OD value for the period of the
lag phase, time t is the lag phase duration in hours, n is the growth
rate expressed in OD6h21, and l is the growth decay constant
expressed in h21. The use of linear components in a nonlinear
equation is a common approach which increases the flexibility of
the equation in order to capture complex phenomena like
Aspergillus dynamic growth. In general, this growth model
assumes linear growth of the population (linear component),
whereas, at the same time, cell death would occur due to ageing
and nutrient consumption (exponential component). The propor-
tion of cell death would increase over time.
Clustering Analysis of Strains Based on the Fungal
Growth
To identify whether there were differences in fungal growth
between the strains, clustering analysis was performed on their
growth parameters (t,n,l) as follows: Each parameter was
standardized by computing its z-score. Then, since the number
of clusters was unknown, we created an agglomerative hierarchical
cluster tree by applying the centroid linkage method (UPGMC)
with the Euclidean distance.
The quality of agglomerative clustering was assessed by the
cophenetic correlation coefficient (CPCC). The significance of
clustering was estimated by computing the probability of obtaining
the CPCC by chance as follows: Given a group of N strains, we
generated 106 random samples of N objects (‘‘random’’ strains)
with coordinates from the same range as the given N strains. Then,
parameters of each random sample were z-score standardized and
the objects were clustered by the same agglomerative technique as
the original data. CPCC was computed for each random sample
(CPCCi). As a result, we accumulated the distribution of CPCCis
for these clusterings (CR= {CPPCi | i M {1,2,…,106} }) and we
counted how many times CPCCi was equal to or greater than the
cophenetic correlation CPCCS of the clustering original strains
(C= {CPCCi M CR | CPCCi $ CPCCS }). Then, the empirical p
value of the original clustering was determined as
P~
DCD
DCRD
If clustering of the original strains was significantly better than
clustering of random samples (P,0.05), the derived clustering
structure had a low probability of being obtained by chance.
The CSI: a New Composite of Survival
For in vivo studies, survival data for each inoculum is analyzed
based on the Kaplan Meier method (log-rank test), and SUR% and
MST is determined. SUR% is calculated as the number of survivors
over the total number of infected animals at the end of the
experiment.MST is the time at which the fractional survival equals
50% (GraphPad Prism, version 5.0). For inocula where 50%
mortality is not observed within the predefined time interval, MST
is considered as maximum MST (MSTmax) equal to the day of
termination of the experiment.
Although, SUR% is considered to be a measure for estimating
virulence in general, it does not take into account MST, which is
also an outcome of Kaplan Meier analysis. We therefore propose a
new composite index of these two parameters of survival, the CSI.
CSI is defined to include both terms as follows:
CSI~1{
SUR%|MST
100%|MSTmax
ð2Þ
where MSTmax is the length of the in-vitro experiment, which equals
to the day of termination of the experiment. The denominator of
the second term is a normalizing constant that restricts CSI
between 0 and 1. CSI corresponds to the degree and rate of
mortality, for which high mortality corresponds to high CSI. The
CSI itself is used here as a direct measure of virulence, but can be
applied as an index value for any survival curve.
Correlation between Fungal Growth and CSI
A multiple logistic regression analysis was employed to
determine the relationship between virulence markers and fungal
growth-curve parameters. Logistic functions were used to fit three
Prediction of Virulence in Aspergillus Fumigatus
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different virulence markers as follows
MST*
MSTmax
1ze{g(t,n,l)
, SUR%*
100
1ze{g(t,n,l)
, CSI*
1
1ze{g t,n,lð Þ
,
in which g t,n,lð Þ is the following function of growth parameters:
g t,n,lð Þ~atzbnzcl: ð3Þ
a, b, and c are regression coefficients. Virulence was quantified by
using MST, SUR%, and CSI. Thus, for all virulence measurements
(response-dependent variables), the regression coefficients were
estimated independently. In addition, the regression for each
response model was cross-validated by using Stein formula [38] of
adjusted R2 to assess the loss of predictive power of each response
model.
Comparison of the Virulence-marker Models
The two virulence markers with the best goodness of fit were
compared to assess which was explained better by the growth
parameters. To this end, we computed standardized residuals for
each of the two response models using leave-one-out cross
validation.
Given a model, one response value was omitted and the
multiple logistic regression analysis was performed on the
remaining response values to estimate the regression coefficients.
Afterwards the removed response was predicted by the logistic
function by using the estimated coefficients. The standardized
residual (R) of the predicted value (Vpred) and the observed value
(Vobs) of the omitted response was computed by using the formula
R~
DVpred{VobsD
std Vð Þ ,
in which std Vð Þ was the sample standard deviation of all response
values. The procedure was repeated for each response value. For
each strain, we compared the standardized residuals of response
values of both models: the lower the standardized residuals, the
better the fit.
Construction of a General Model
The logistic function-based model given by Equation 4 was used
to incorporate the four-dimension dataset as a general model in
which CSI was associated with growth-curve parameters (t,n,l) and
inoculum size, W:
CSI*
1
1z exp (d(EC50{(atzbnzclz log (W))))
ð4Þ
in which EC50 is a parameter associated with a CSI value of 0.5.
Results
Phenotype and in vitro Growth Characteristics
The in vitro susceptibility phenotype to itraconazole, posacona-
zole, and voriconazole, the underlying resistance mechanism, and
the short tandem repeat (STR) profile of the 30 clinical A. fumigatus
isolates are shown in Table S1. The recently proposed interpre-
tative breakpoints were used to categorize the phenotypes of the
isolates [39]. For each isolate, the growth curve was characterized
using a microbroth kinetic system [34,37]. In this system,
microscopic examination has confirmed that an increase in the
optical density corresponds to the multicellular development of A.
fumigatus [37]. Previously multiple phases (lag phase, log phase, and
two transition phases) were identified to describe the growth of A.
fumigatus in vitro [37], however our novel mathematical model
identified only two phases; the lag phase and the decaying linear
OD growth phase, the latter including the log and two transition
phases (Fig. 1, Equation 1). The proposed growth function
describes the first phase through the duration of the lag phase (t),
and the second phase by the linear OD growth rate (n) and the
decay constant (l). The stationary phase was not observed during
the incubation period of 90 h. The mathematical model of growth
fitted well to the observed growth curves (Fig. S1) with R2 values
ranging from 0.98 to 0.99 with no zero value within the 95%CI of
the model parameters for all isolates (Table S2). The correlation
study of the growth parameters (t,n,l) revealed that two
parameters, n and l, exhibit a high and statistically significant
linear correlation (Table 1). Despite this correlation, the CSI
measure using both growth parameters can be still applied as a
predictive tool which is verified by F-test on nested models of CSI
(Table 4).
Differential Survival Outcomes Reflect a Strain-
dependent Virulence Distinction
To explore whether there was a variation in virulence of our
strains in vivo, we performed survival experiments with 15 A.
fumigatus strains using 4 different inocula for each strain. Table 2
depicts differential survival rates for each strain of mice groups
inoculated with the same lethal or sublethal inoculum. Suscepti-
bility to infection was most prominent in animals infected with an
inoculum of 56107 CFU and no clear differences in percentage of
survival (SUR%) and median survival time (MST) were observed,
with exception of two strains. In mice infected with azole-resistant
isolates R1 and R2, 100% mortality occurred in a time period that
Figure 1. Modeling of the in vitro growth in A. fumigatus. In the
figure is depicted an example of model fit to a single isolate. The
growth is characterized by five phases: the lag phase, where no OD-
growth changes were observed; the 1st transition period, where the OD
change rate increased; the log phase, where the OD change rate was
maximal; and the 2nd transition period, where the OD change rate
decreased to reach a stationary phase. The output of the mathematical
model developed herein shows that two phases are critical to measure
fungal growth in vitro: a) the lag phase and b) the linear OD decaying
growth phase, which includes the 1st and 2nd transition periods and
the log phase. The proposed model (Equation 1) for simulating the
growth of A. fumigatus in vitro (blue line) fitted well to the observed
growth curves (red line).
doi:10.1371/journal.pone.0072280.g001
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was significantly longer than the other groups (p,0.05). Lower
mortality and longer MST was also observed at the inoculum of
107 CFU (p,0.05). In contrast, mice infected with the parental S2
rapidly succumbed at a dose of 106 conidia and 56106, while these
concentrations showed a sublethal outcome in the case of infection
with wild type or any of the other mutants. Moreover, both highest
inocula concentrations resulted in lowest survival in shortest time
compared to all other groups (Table 2). Similarly, the second
lowest SUR% with short MST was found for the groups infected
with the G54W mutant, however, mainly for the two lowest
inocula.
As our survival data suggested a wide variation in the virulent
traits of some strains-, we next addressed the question if the
observed variation in SUR% and MST could be correlated with
characteristics of the in vitro growth curves. Furthermore, to
improve the sensitivity to detect in vivo virulence differences, we
developed a dynamic marker, the Composite Survival Index (CSI),
which describes the rate (MST) and extent of killing (SUR%)
(Equation 2).
Cluster Analysis Reveals Heterogeneous Growth within
the Wild Type and Azole-resistant Populations
A clustering approach was applied to the growth-curve
parameter (t,n,l) estimates of all strains to explore primary
differences in growth between the wild type and the non-wild type
isolates more accurately (Fig. S2 & Fig. 2). Statistical analysis
revealed that clustering was significantly better than that found for
a random population (CPCC=0.922, p,1026). Interestingly,
there was no single-cluster formation of the wild type population,
indicating that the wild type strains did not share similar growth
characteristics. Similarly, no single cluster was observed for any of
the strains harboring cyp51A mutations (Fig. 2).
Virulence in A. fumigatus is Related to Growth
To determine whether growth of A. fumigatus was associated with
virulence, we investigated the relationship between MST, SUR%,
the new proposed Composite Survival Index (CSI) and the growth
properties (t,n,l) of each strain. This index incorporates both
SUR% and MST and may be viewed as an indicator of virulence of
a strain (Equation 2). Multiple logistic regression analysis was used
to fit in vitro growth characteristics t, n, and l to all three virulence
markers (Fig. 3). For each virulence marker, the fitting procedures
estimated different regression coefficients (a, b, c) (Table 3).
While regression analysis revealed a weak correlation between
MST and the growth properties (R2 =0.36; Fig. 3A), a strong
correlation was found for the other two responses (for SUR%
R2=0.84, for CSI R2=0.92; Fig. 3B & 3C).
Regression coefficients a, b, and c for the growth parameters t, n
and l (Equation3), respectively, associated with CSI, were as
follows: a=20.51 (95%CI: 20.72, 20.29), b=1835.78 (95%CI:
Table 1. Sample correlation coefficients between the growth parameters (t,n,l).
Correlation
Coefficients t n l p-values t n l
t 1 20,0022 0,1534 t 1 0,9938 0,5851
n 20,0022 1 0,8651 n 0,9938 1 0,000031
l 0,1534 0,8651 1 l 0,5851 0,000031 1
doi:10.1371/journal.pone.0072280.t001
Table 2. Differential survival outcome reflects strain-dependent virulence distinction.
Isolates Inoculum 10
6 CFU Inoculum 56106 CFU Inoculum 107 CFU Inoculum 56107 CFU
SUR% MST SUR% MST SUR% MST SUR% MST
WT (AZN 8196) 100 15 72.72 15 18.18 8 0 3
WT (V52–76) 63.63 15 36.36 12 9.09 4 0 2
WT (V28–29) 100 15 63.63 15 0 6 0 2
TR34/L98H (V52–35) 90.90 15 45.45 8 18.18 8 0 3
TR34/L98H (V45-07) 100 15 27.27 11 45.45 11 0 2
TR34/L98H (V61–76) 100 15 18.18 8 0 4 0 2
M220I_V28–77 81.81 15 63.63 15 0 7 18.18 5
M220K_V59-27 100 15 63.63 15 45.45 12 0 2
M220V_V13-09 81.81 15 9.90 10 9.09 9 0 2
G54W_V59–73) 45.455 8 0 8 0 4 0 3
G138C_V59–72 90.09 15 54.54 15 0 6 0 2
S1_V67-38 90.09 15 63.63 15 36.36 15 0 2
S2_V67-37 36.36 5 0 2 0 2 0 1
R1_V67-36 100 15 90.09 15 90.09 15 0 6
R2_V67-35 100 15 100 15 63.63 15 0 6
doi:10.1371/journal.pone.0072280.t002
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1043.1, 2628.5), c=2526.92 (95%CI: 21009.6, 244.23). The
negative coefficients a and c indicate a negative relationship
between the respective growth characteristics t and l and the CSI.
This means that the longer the lag phase and the higher the decay
constant, the lower the CSI value. In other words, strains with a
low CSI value are less virulent. The positive coefficient b indicates
a positive relationship between the growth rate n and CSI, which
means that strains with a high growth rate have high CSI values.
The linear combination g(t,n,l) of the growth parameters
(Equation 3) combined with the estimated regression coefficients
for CSI provides a good measure of the virulence of any given A.
fumigatus isolate. Accordingly, an isolate with g(t,n,l)= 0, will have
a CSI of 0.5, which corresponds to 50% SUR% and an MST of 15
days. This is also the case for any other combination of SUR% and
MST that results in a CSI of 0.5 based on Equation 2. By
definition, CSI is always less than or equal to 1-SUR%. Thus, a
CSI of up to 0.5 is obtained only with a SUR% of at least 50%.
Figure 3B and 3C show, for the SUR% and CSI models, that the
virulence of the two azole-resistant isogenic isolates, R1 and R2,
was reduced relative to the other isogenic azole susceptible isolates
and all other strains. Specifically, the SUR% in mice exposed to
infection by R1 and R2 was greater than 60% and g(t,n,l) was
greater than 0. Two other isolates with mutations in cyp51A
(TR34/L98H_45-07 and M220K) were less virulent than all WT
isolates and the other cyp51A mutants. Eleven out of 15 isolates
displayed a high CSI of 0.9, which corresponded with an increased
probability of death when the value of g(t,n,l) exceeded 2.2.
To verify whether all growth characteristics were significant for
the CSI model, we additionally performed multiple regressions on
models with reduced numbers of growth parameters. The F-test
comparison of the original and nested models revealed that a
reduction in each parameter resulted in a significant decrease in
the performance of the model (Table 4). Table 4 also shows that
extending the original model by Y0 parameter did not lead to
statistically significant improvement of the fit.
The Novel Composite Survival Index is the Superior
Virulence Marker
We performed a comparative leave-one-out cross-validation
study between the SUR% and the CSI models to verify the
superiority of CSI over SUR%. Figure 4 demonstrates that the CSI
model describes the relationship between fungal growth and
virulence better than the SUR% model because 12 of the 15
isolates had less standardized residuals for CSI than for SUR%
(Fig. 4, markers below the diagonal). To test the significance of the
improvement in the residual values, we applied a binomial
statistical test, which showed that the CSI model was significantly
better than the SUR% model (p,0.02).
Prediction of Virulence via CSI
Mice survival for the aforementioned studies was assessed
following an infection of 107 CFU per mouse. To further confirm
the validity of CSI, we carried out the infection in groups with
three additional doses of conidia. Figure 5 depicts the resulting CSI
versus the function g(t,n,l) relationships for four different inocula.
There was no clear sigmoidal relationship between CSI and g(t,n,l)
for the groups infected with 16106, 56106, and 56107 CFU per
mouse. In panel with an infection of 106 CFU, only the initial,
shallow part of the sigmoidal shape of the CSI curve is apparent,
whereas increasing the concentration to 56106 results in a steeper
gradient of the curve. Lastly, the highest infection concentration of
56107 was associated with reaching the plateau of the sigmoidal
curve and results in no differentiation between the different strains.
As expected, different inocula affected the virulence of
individual isolates, indicating that CSI was also dependent on the
inoculum size. Therefore, we defined a general model for
Figure 2. Clustering analysis of strains based on the fungal
growth. The growth-curve parameter (t,n,l) estimates of 30 strains
revealed interstrain variability in growth within the WT groups and the
non-wild-type isolates. The subscripts indicate the ID numbers of each
A. fumigatus strain used for the current study.
doi:10.1371/journal.pone.0072280.g002
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predicting the virulence of a strain based on the initial inoculum
(W) and the growth of the strains (Fig. S3; Equation 4).
Nonlinear multiple regression analysis showed the ability of the
model to predict virulence, as shown by the good overall statistics
of the fit (R2=0.82, p,0.001; Fig. S3). The mean (95%CI)
estimates of the regression coefficients a, b, c, d and the EC50 was
20.06 (20.10, 20.01), 207.03 (111.45, 307.24), 2156.42
(2266.68, 258.31), 3.81 (2.74, 5.96) and 6.60 (6.01, 7.13),
respectively.
Discussion
The primary aim of our study was to determine the impact of
acquisition of azole resistance by A. fumigatus on virulence and to
determine which in vitro growth characteristics are critical for
in vivo survival. Our in vivo experiments showed that virulence,
expressed as SUR% and MST, is variable, even between wild type
isolates, and that azole-resistant clinical A. fumigatus isolates with
cyp51A mutations are not less virulent. However, development of
azole resistance may be associated with loss of virulence as was
Figure 3. Relationship between the virulence markersMST, and SUR % and CSI and the function g(t,n,l). The logistic function was used to
fit three different virulence markers: the median survival time (MST, panel A), the survival percentage (SUR %, panel B) and the composite survival
index (CSI, panel C). No in vitro-in vivo correlation was found between MST and g(t,n,l), whereas a strong correlation was found for the other two
virulence markers. The symbols correspond to the observed CSI values, while the solid line is the outcome of the prediction model.
doi:10.1371/journal.pone.0072280.g003
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apparent with the set of four isogenic isolates, where the transition
from an azole-susceptible phenotype to an azole-resistant pheno-
type was associated with higher SUR% and MST. A novel non-
cyp51A mediated resistance mechanism was recently reported in
these isolates, which consisted of a mutation in the CCAAT-
binding transcription factor complex subunit HapE [40].Although
the ergosterol biosynthesis pathway is critical for growth and
proliferation of the fungus (and thus is an important drug target), it
has previously been shown that SNPs in the cyp-gene of Candida
occurred without major perturbation of the haem environment or
activity, and as a consequence, allowed resistant mutants to
produce ergosterol and retain fitness [41]. Our study suggests that
this may also be the case in A. fumigatus that harbor SNPs in
cyp51A. Although the exact role of HapE is not yet understood,
isolates with the HapE mutation exhibited altered growth
characteristics, such as impaired growth, suggesting that this
mutation has implications for a broad range of processes in the
fungal cell.
From a clinical perspective our observations are of importance
as they indicate that A. fumigatus isolates with an azole-resistant
phenotype due to a cyp51A-mediated resistance mechanism are
capable of causing a similar spectrum of azole diseases as the wild-
type isolates [10,11,12,21,28,42].
This supports the clinical experience of increasing reports of
cases of non-invasive and invasive aspergillosis due to azole-
resistant isolates, and the high probability of failure during azole
therapy [12,43]. Furthermore, for TR34/L98H mutations, which
are considered to have developed through exposure to 14a-
demethylase inhibitors (DMIs), any fitness loss would be an
important disadvantage when competing with wild-type field
isolates. Our findings indeed indicate that the virulence of TR34/
L98H isolates is comparable to wild type controls [8] as there is no
growth impairment and thus no reduction of virulence.
In order to correlate in vitro growth characteristics with the
in vivo markers of virulence a mathematical model was developed
that indicated that three growth parameters, the lag phase, the
growth rate (n) and the decay constant (l) were critical for
virulence. Our model elucidates how these three parameters
interact with each other and are associated with virulence
expressed as the CSI. For instance, a long lag phase (t) and high
decay constant (l) resulted in a low CSI and in low virulence;
whereas high CSIs and virulence was characterized by rapid
growth (n) and short lag phases. However, the individual
parameters can vary between isolates with similar CSIs. The wild
type isolate V52–76 had the same CSI as the G54W mutant
(g=3.4; CSI=0.96), although isolate V52–76 was characterized by
a lower decay constant and shorter lag phase than the G54W
mutant. The growth rate of G54W, however, was faster compared
to isolate V52–76, which compensated for the other two growth
parameters. Overall, a CSI of 0.9 corresponded with a high
probability of death when the value of g(t,n,l) exceeded 2.2.
Analysis of residuals showed that the CSI correctly predicted
virulence of each strain with a difference between estimated and
observed CSI to be #0.1 for almost all isolates except for one
group infected with TR34/L98H (isolate V45-07) for which a
greater than 0.1 residual was found (Table 5). This may indicate
Table 3. Descriptive statistics of fitting the g(t,n,l) function against the composite survival index (CSI), the percentage of survival
(SUR%) and the median survival time (MST) for the inoculum 107 CFU.
Regression coefficients (95% CI ±) R2 R2adj MSE
a b c
MST 0.162 (20.071, 0.395) 2501.294 (21054.08, 51.497) 367.81(2195.07, 930.7) 0.37 20.12 11.85
SUR% 0.354 (0.122, 0.586) 21562.45 (22472.47, 2652.43) 968.64 (80.79, 1856.48) 0.82 0.68 162.4
CSI 20.511 (20.741, 20.281) 1887.502 (983.5, 2791.51) 2988.59 (21782.6, 2194.6) 0.91 0.84 0.007
MSE, mean squared error;
doi:10.1371/journal.pone.0072280.t003
Table 4. The F-test statistics of nested CSI models compared
to the original CSI model.
Growth parameters kept F p-value
tn 27.76 0.0002
tl 134.14 7.17610208
nl 43.36 2.59610205
t 78.33 1.30610207
n 54.11 9.89610207
l 67.87 2.87610207
tnlY0 4.61 0.055
The last row demonstrate F statistics when the original model is nested with
respect to the extended model by adding Y0 into the linear term g(t,n,l).
doi:10.1371/journal.pone.0072280.t004
Figure 4. Leave one out-cross validation analysis. The CSI model
describes the relationship between fungal growth and virulence better
than the SUR% model because 12 of the 15 isolates had less
standardized residuals for CSI than for SUR% (markers below the
diagonal) (p,0.02). The shapes and colors of the symbols used for the
observed data represent the same isolates as those defined in Figure 3.
doi:10.1371/journal.pone.0072280.g004
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that other factors than growth may play role in virulence of this
strain related with host and/or fungus. For example, immunogenic
molecules on the fungal cell wall surface that affect docking and
pathogen recognition result in reduced virulence [44], whereas
spore production, spore decay, spore settlement, spore germina-
tion, and mycelia growth rate are important fitness components
for fungi [36]. Interestingly, a change in virulence was also
observed and correctly predicted by the model for the M220K
isolate. The CSI was approximately 0.5 times lower than that of
the wild type isolates and the other cyp51A mutants, and around
0.5 times greater than the least virulent isolates R1 and R2,
indicating reduced virulence. If as stated above cyp51A-mutations
have little or no fitness costs, differences in virulence such as
observed in the M220K are probably due to changes in other
genes or pathways, similar to those that may occur in wild type
isolates. As we used clinical isolates and the resistance mechanism
as selection criterion, the genetic background of our isolates will
vary significantly. The use of recombinants would be an interesting
next approach to further explore the contribution of individual
SNPs on the virulence of A. fumigatus.
The CSI may be a useful tool to determine the impact of
mutations on virulence. Moreover, the use of a general model
(Equation 4) allows prediction of virulence in vivo, thereby reducing
the number of animals required in such experiments. We have
applied this tool in our laboratory to allow us to calculate the
inoculum required for studies; this has led to substantial savings in
time and animals.
In our study, we employed a relative simple and conservative
murine model of aspergillosis. We used a nonneutropenic model,
although patients with invasive aspergillosis often suffer from
neutropenia and the opportunistic fungus is believed to be only
infective when patients carry immunodeficiencies in one way or
another. Once the fungal growth overcomes the immune defense
the progress of the disease starts. This bears similarity to the model
used. Mice are susceptible to conidia in high amounts and by
increasing the infection-dose mortality increased. We could
therefore avoid the use of immunosupressors that has been
Figure 5. Relationship between CSI and g(t,n,l) by systemic infection of mice with four different inocula. No clear sigmoidal relationship
was found between CSI and g(t,n,l) for the groups infected with 16106, 56106, and 56107 CFU per mouse. Changes in the virulence of each single
strain due to different inocula indicate that CSI was also dependent on the degree of infection by the inoculums.
doi:10.1371/journal.pone.0072280.g005
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described to alter A. fumigatus growth and thereby affect the
interpretation of our results [25,45]. Moreover, the long-term
effects of immunosuppressors on the fungus or host are almost
completely unknown. Regarding the route of infection, there are
two reasons for having chosen the disseminated model as opposed
to an inhalation model. First, this infection model is well
established and allows excellent control of infection parameters
(such as inoculum), whereas the pulmonary model comes in a
variety of forms with several technical problems including less well
controlled infection. Secondly, Thomas and Elkinton reported that
virulence and infectivity can primarily be measured when
experimental infections occur through the intravenous portal
because it involves establishment and spread within the host [46].
Multiple factors require investigation in the context of
comparative virulence. We here focused on one aspect, the
growth characteristics and conclude that these have a major
impact on survival and virulence in the process of disseminated
aspergillosis. Specific virulent factors relevant to conidial entry into
the lungs, binding or germination at that site were not tested in this
model. However, previous reports demonstrated the complexity of
virulence and suggested that this complex host-microbe interaction
can only be measured by the use of a multivariate mathematical
model which will comprise multiple potential microbial and host
factors of this interaction [47]. To understand the differential
response of the host to fungal challenge, it is necessary to expand
upon this basis in future studies.
Supporting Information
Figure S1 Fitting of the in vitro growth curves of fifteen
A. fumigatus isolates. The proposed model (Equation 1) for
simulating the growth of A. fumigatus in vitro (blue line) fitted well to
the observed growth curves (red line) of fifteen clinical isolates with
R2 values ranging from 0.98 to 0.99.
(TIF)
Figure S2 Distribution of the wild-type population and
populations with diverse cyp51A mutations. Azole suscep-
tible isolates (wild-type population) are black colored; red color,
TR34/L98H mutants; blue, isogenic resistant strains R1 and R2;
cyan, isogenic susceptible strains S1 and S2; green, M220I,
M220K, M220V, TR46/L98, G138C, G54W.
(TIF)
Figure S3 Prediction of CSI based on the inoculum size
and the growth characteristics. Graphs depicting the
goodness of fit (R2 = 0.82, p,0.001) of the full general model
predicting CSI based on the growth-curve parameters t, n and l
and the inoculum size W (the four inocula are depicted with
different colors) for the fifteen A. fumigatus strains.
(TIF)
Table S1 Characteristics of thirty clinical A. fumigatus
isolates used in our studies.
(DOC)
Table S2 In vitro growth characteristics and growth
phase fit of thirty clinical A. fumigatus isolates.
(DOC)
Acknowledgments
We are grateful to Antonius J. M. M. Rijs and Henrich A. L. van der Lee
for providing assistance and technical advice. We thank Simone M. T.
Camps for providing the STR profile of the strains.
Author Contributions
Conceived and designed the experiments: EM JM JWM PEV. Performed
the experiments: EM. Analyzed the data: EM JM JWM PJ SA TH.
Contributed reagents/materials/analysis tools: WJGM MCA. Wrote the
paper: EM JM PJ JWM PEV. Provided molecular data: WJGM. Designed
and supervised the mathematical analysis: TH. Critical revision for
important intellectual content: MCA.
References
1. Capilla J, Clemons KV, Stevens DA (2007) Animal models: an important tool in
mycology. Med Mycol 45: 657–684.
2. Tekaia F, Latge JP (2005) Aspergillus fumigatus: saprophyte or pathogen? Curr
Opin Microbiol 8: 385–392.
3. Clemons KV, Stevens DA, Gilead (2006) Animal models of Aspergillus infection
in preclinical trials, diagnostics and pharmacodynamics: What can we learn from
them? Med Mycol 44: 119–126.
4. Willger SD, Grahl N, Cramer RA, Jr. (2009) Aspergillus fumigatus metabolism:
clues to mechanisms of in vivo fungal growth and virulence. Med Mycol 47 Suppl
1: S72–79.
5. Braga PC, Sasso MD, Sala MT (2000) Sub-MIC concentrations of cefodizime
interfere with various factors affecting bacterial virulence. J Antimicrob Che-
mother 45: 15–25.
6. Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF
(2011) Caspofungin dose escalation for invasive candidiasis due to resistant
Candida albicans. Antimicrob Agents Chemother 55: 3254–3260.
7. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, et al.
(1997) Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents
Chemother 41: 1364–1368.
8. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, et al. (2008)
Emergence of azole resistance in Aspergillus fumigatus and spread of a single
resistance mechanism. PLoS Med 5: e219.
9. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ (2009) Azole
resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Lancet 9: 789–795.
10. van der Linden JWM, Jansen RR, Bresters D, Visser CE, Geerlings SE, et al.
(2009) Azole-Resistant Central Nervous System Aspergillosis. Clin Infect Dis 48:
1111.
11. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE (2007)
Aspergillosis–and a misleading sensitivity result. Lancet 370: 102.
Table 5. Rank of the fifteen clinical A. fumigatus isolates used
for the evaluation of virulence in a murine model of
disseminated aspergillosis based on the observed CSIs.
Isolates (_ID number) g(t,n,l) Predicted CSI Observed CSI
WT_V28–29 5.6853 0.9967 1
TR34/L98H_V61–76 3.8431 0.9814 1
G54W_V59–73) 3.4642 0.975 1
G138C_V59–72 3.2132 0.9621 1
S2_V67–37 3.0882 0.954 1
M220I_V28–77 2.7105 0.9363 1
WT_V52–76 3.4303 0.9689 0.9758
M220V_V13-09 8.4007 0.9997 0.9455
TR34/L98H_V52-35 7.3526 0.9993 0.9030
WT_AZN 8196 4.0605 0.9825 0.9030
S1_V67-38 1.7368 0.8536 0.8788
TR34/L98H _V45-07 1.9441 0.8944 0.6667
M220K_V59-27 0.2702 0.5594 0.6364
R2_V67-35 20.6141 0.347 0.3636
R1_V67-36 21.6555 0.1769 0.091
doi:10.1371/journal.pone.0072280.t005
Prediction of Virulence in Aspergillus Fumigatus
PLOS ONE | www.plosone.org 10 August 2013 | Volume 8 | Issue 8 | e72280
12. Howard SJ, Cerar D, Anderson MJ, Albarrag A (2009) Frequency and evolution
of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg
Infect Dis 15: 1068–1076.
13. Verweij PE, Mellado E, Melchers WJ (2007) Multiple-triazole-resistant
aspergillosis. N Engl J Med 356: 1481–1483.
14. van der Linden JWM, Snelders E, Kampinga GA, Rijnders BJA, Mattsson E, et
al. (2011) Spread and clinical impact of azole-resistance in Aspergillus fumigatus.
Emerg Infect Dis 17:1846–1854.
15. Willger SD, Puttikamonkul S, Kim KH, Burritt JB, Grahl N, et al. (2008) A
sterol-regulatory element binding protein is required for cell polarity, hypoxia
adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS
Pathog 4: e1000200.
16. Chang YC, Bien CM, Lee H, Espenshade PJ, Kwon-Chung KJ (2007) Sre1p, a
regulator of oxygen sensing and sterol homeostasis, is required for virulence in
Cryptococcus neoformans. Mol Microbiol 64: 614–629.
17. Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Moller N,
et al. Development of azole resistance in Aspergillus fumigatus during azole therapy
associated with change in virulence. PLoS One 5: e10080.
18. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL (2001)
Identification of two different 14-alpha sterol demethylase-related genes (cyp51A
and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol
39: 2431–2438.
19. Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, et al. (2003)
Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posacona-
zole appear to be restricted to a single amino acid in the cytochrome P450
14alpha-demethylase. Antimicrob Agents Chemother 47: 577–581.
20. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-
Tudela JL (2004) Substitutions at methionine 220 in the 14alpha-sterol
demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro
to azole antifungal drugs. Antimicrob Agents Chemother 48: 2747–2750.
21. Nascimento AM, Goldman GH, Park S, Marras SAE, Delmas G, et al. (2003)
Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-
Level Resistance to Itraconazole. Antimicrob Agents Chemother 47: 1719–
1726.
22. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE (2010)
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with
mutations in the cyp51A gene. Antimicrob Agents Chemother 54: 860–865.
23. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW (2010)
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic
properties of voriconazole in a murine model of disseminated aspergillosis.
Antimicrob Agents Chemother 54: 4758–4764.
24. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, et al.
(2011) Clinical implications of azole resistance in Aspergillus fumigatus, The
Netherlands, 2007–2009. Emerg Infect Dis 17: 1846–1854.
25. Mondon P, De Champs C, Donadille A, Ambroise-Thomas P, Grillot R (1996)
Variation in virulence of Aspergillus fumigatus strains in a murine model of invasive
pulmonary aspergillosis. J Med Microbiol 45: 186–191.
26. Clemons KV, Stevens DA (2005) The contribution of animal models of
aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol
43 Suppl 1: S101–110.
27. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, et al. (2011)
Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global
surveillance study is primarily due to the TR/L98H mutation in the cyp51A
gene. Antimicrob Agents Chemother 55: 4465–4468.
28. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, et al. (2012)
Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the
TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 67:
362–366.
29. Mortensen KL, Mellado E, Lass-Florl C, Rodriguez-Tudela JL, Johansen HK,
et al. (2010) Environmental study of azole-resistant Aspergillus fumigatus and other
aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 54:
4545–4549.
30. Snelders E, Huis In’t Veld RA, Rijs AJ, Kema GH, Melchers WJ, et al. (2009)
Possible environmental origin of resistance of Aspergillus fumigatus to medical
triazoles. Appl Environ Microbiol 75: 4053–4057.
31. de Valk HA, Meis JF, Curfs IM, Muehlethaler K, Mouton JW, et al. (2005) Use
of a novel panel of nine short tandem repeats for exact and high-resolution
fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol 43: 4112–4120.
32. Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Lopez JF, Grimalt JO, et al.
(2008) Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids 73: 339–
347.
33. Clinical Committee for Clinical Laboratory S (2002) Reference method for
broth dilution antifungal susceptibility testing of filamentous fungi. Approved
standard. NCCLS document M38-A: National Committee for Clinical
Laboratory Standards, Wayne, PA.
34. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, et al. (2001)
Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin
Microbiol 39: 3402–3408.
35. Meletiadis J, te Dorsthorst DT, Verweij PE (2003) Use of turbidimetric growth
curves for early determination of antifungal drug resistance of filamentous fungi.
J Clinic microbiol 41: 4718–4725.
36. Pringle A, Taylor J (2002) The fitness of filamentous fungi. Trends Microbiol 10:
474–481.
37. Meletiadis J, Meis JF, Mouton JW, Verweij PE (2001) Analysis of growth
characteristics of filamentous fungi in different nutrient media. J Clin Microbiol
39: 478–484.
38. Stevens JP, editor (1992) Applied multivariate statistics for the social sciences
(Hillsdale, NJ: Erlbaum.).
39. Verweij PE, Howard SJ, Melchers WJ, Denning DW (2009) Azole-resistance in
Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 12: 141–
147.
40. Camps SM, Dutilh BE, Arendrup MC, Rijs AJ, Snelders E, et al. (2012)
Discovery of a HapE mutation that causes azole resistance in Aspergillus
fumigatus through whole genome sequencing and sexual crossing. PLoS One 7:
e50034.
41. Schrettl M, Beckmann N, Varga J, Heinekamp T, Jacobsen ID, et al. (2010)
HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus
fumigatus. PLoS Pathog 6: e1001124.
42. Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A (2011)
Impact of therapeutic drug monitoring of voriconazole in a pediatric population.
Pediatr Infect Dis J 30: 533–534.
43. van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE, et al.
(2009) Azole-resistant central nervous system aspergillosis. Clin Infect Dis 48:
1111–1113.
44. Aimanianda V, Bayry J, Bozza S, Kniemeyer O, Perruccio K, et al. (2009)
Surface hydrophobin prevents immune recognition of airborne fungal spores.
Nature 460: 1117–1121.
45. Ng TT, Robson GD, Denning DW (1994) Hydrocortisone-enhanced growth of
Aspergillus spp.: implications for pathogenesis. Microbiology 140 (Pt 9): 2475–
2479.
46. Thomas SR, Elkinton JS (2004) Pathogenicity and virulence. J Invertebr Pathol
85: 146–151.
47. McClelland EE, Bernhardt P, Casadevall A (2006) Estimating the relative
contributions of virulence factors for pathogenic microbes. Infect Immun 74:
1500–1504.
Prediction of Virulence in Aspergillus Fumigatus
PLOS ONE | www.plosone.org 11 August 2013 | Volume 8 | Issue 8 | e72280
